scholarly journals Pisa Biobank and Tuscany Regional Biorepository

2020 ◽  
Author(s):  
Francesca Nocchi ◽  
Patrizia Urciuoli ◽  
Silvia Ursino ◽  
Elisa Biagi ◽  
Simone Lapi
Keyword(s):  
Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Tissue Donors ◽  
Viable Cells ◽  
Advanced Therapy ◽  
Class B ◽  
Solid Organ Transplant Recipients ◽  
Expanded Mesenchymal Stem Cells ◽  
Therapy Protocol

Departmental Section of Biobanks (SOD Biobanche) of the Azienda Ospedaliera Universitaria Pisana, consists of a Tissue and Cell institute, the Heart Valve Bank, and a biorepository, the Regional Biologic Archive. A clean room consisting of three laboratories (1 class C and 2 class B) represents a core facility for some of the processes and projects of the biobank. The Regional Biological Archive is a biobank which currently carries out as an institutional task the storage of serum, plasma and non-viable cells of multiorgan, multi-tissue donors and donors of corneas, as well as solid organ transplant recipients of the Tuscany Region, providing the possibility of reviewing and re-evaluating even at a distance of years the donor/recipient pairs. The mission of SOD Biobanche is to act as a transversal service platform in the field of biobanking of biological material. In this broader perspective the structure is open to new projects concerning biobanking, some of which are already in the activation phase, such as a bank for urogenital tissues, a biobank of tumors of the musculoskeletal system and an advanced therapy protocol for the use of partially osteoinduced expanded mesenchymal stem cells.

Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions

2020 ◽  
Vol 26 (28) ◽  
pp. 3497-3506
Author(s):  
Raymund R. Razonable
Keyword(s):  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Future Directions ◽  
Prevention And Treatment ◽  
Solid Organ Transplant Recipients

Cytomegalovirus is the classic opportunistic infection after solid organ transplantation. This review will discuss updates and future directions in the diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients. Antiviral prophylaxis and pre-emptive therapy are the mainstays of CMV prevention, but they should not be mutually exclusive and each strategy should be considered depending on a specific situation. The lack of a widely applicable viral load threshold for diagnosis and preemptive therapy is emphasized as a major factor that should pave the way for an individualized approach to prevention. Valganciclovir and intravenous ganciclovir remain as drugs of choice for CMV management, and strategies for managing drug-resistant CMV infection are enumerated. There is increasing use of CMV-specific cell-mediated immune assays to stratify the risk of CMV infection after solid organ transplantation, and their potential role in optimizing CMV prevention and treatment efforts is discussed.

Sign in / Sign up

Export Citation Format

Share Document